JOHANNESBURG (Reuters) – Two doses of Pfizer-BioNTech’s COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant. Read full story



